Rhythm Pharmaceuticals (RYTM) Competitors $88.30 +3.07 (+3.60%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$86.20 -2.10 (-2.38%) As of 08/1/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RYTM vs. SMMT, INSM, TEVA, GMAB, MRNA, RDY, QGEN, VTRS, ASND, and BBIOShould you be buying Rhythm Pharmaceuticals stock or one of its competitors? The main competitors of Rhythm Pharmaceuticals include Summit Therapeutics (SMMT), Insmed (INSM), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. Rhythm Pharmaceuticals vs. Its Competitors Summit Therapeutics Insmed Teva Pharmaceutical Industries Genmab A/S Moderna Dr. Reddy's Laboratories QIAGEN Viatris Ascendis Pharma A/S BridgeBio Pharma Rhythm Pharmaceuticals (NASDAQ:RYTM) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk. Do analysts rate RYTM or SMMT? Rhythm Pharmaceuticals currently has a consensus price target of $91.93, indicating a potential upside of 4.11%. Summit Therapeutics has a consensus price target of $34.67, indicating a potential upside of 28.06%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 3.07Summit Therapeutics 2 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.79 Does the media favor RYTM or SMMT? In the previous week, Rhythm Pharmaceuticals had 5 more articles in the media than Summit Therapeutics. MarketBeat recorded 12 mentions for Rhythm Pharmaceuticals and 7 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.97 beat Rhythm Pharmaceuticals' score of 0.78 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, RYTM or SMMT? Rhythm Pharmaceuticals has a beta of 2.38, suggesting that its stock price is 138% more volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.01, suggesting that its stock price is 201% less volatile than the S&P 500. Do institutionals and insiders have more ownership in RYTM or SMMT? 4.6% of Summit Therapeutics shares are held by institutional investors. 6.1% of Rhythm Pharmaceuticals shares are held by insiders. Comparatively, 84.9% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is RYTM or SMMT more profitable? Summit Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -123.26%. Summit Therapeutics' return on equity of -62.87% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rhythm Pharmaceuticals-123.26% -739.62% -44.27% Summit Therapeutics N/A -62.87%-51.61% Which has better earnings & valuation, RYTM or SMMT? Summit Therapeutics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Summit Therapeutics is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRhythm Pharmaceuticals$130.13M43.17-$260.60M-$2.81-31.42Summit TherapeuticsN/AN/A-$221.32M-$0.34-79.62 SummarySummit Therapeutics beats Rhythm Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RYTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RYTM vs. The Competition Export to ExcelMetricRhythm PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.42B$2.99B$5.48B$9.53BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-31.4217.7428.8623.83Price / Sales43.17178.71371.4466.13Price / CashN/A41.9535.4557.96Price / Book252.298.508.265.54Net Income-$260.60M-$55.06M$3.25B$259.28M7 Day Performance2.14%-3.99%-3.73%-4.67%1 Month Performance31.95%9.58%4.28%4.38%1 Year Performance99.82%6.70%25.85%17.90% Rhythm Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RYTMRhythm Pharmaceuticals3.5477 of 5 stars$88.30+3.6%$91.93+4.1%+88.5%$5.42B$130.13M-31.42140Upcoming EarningsInsider TradeSMMTSummit Therapeutics2.8971 of 5 stars$27.45-4.3%$34.67+26.3%+153.9%$21.29B$700K-80.73110Upcoming EarningsINSMInsmed3.7909 of 5 stars$101.75-2.1%$109.20+7.3%+44.3%$19.72B$363.71M-17.101,271Positive NewsUpcoming EarningsTEVATeva Pharmaceutical Industries3.9777 of 5 stars$16.53-0.1%$24.71+49.5%-12.3%$18.97B$16.54B-14.3736,830News CoveragePositive NewsEarnings ReportGMABGenmab A/S3.6367 of 5 stars$23.09-1.3%$37.80+63.7%-23.2%$15.01B$3.12B13.122,682News CoverageShort Interest ↑MRNAModerna4.4701 of 5 stars$33.91-0.7%$46.11+36.0%-70.7%$13.21B$3.14B-3.885,800Trending NewsEarnings ReportAnalyst ForecastOptions VolumeGap DownRDYDr. Reddy's Laboratories2.2952 of 5 stars$14.71+0.2%$16.95+15.3%-15.5%$12.25B$3.81B22.2827,811QGENQIAGEN3.2115 of 5 stars$51.00-1.5%$49.40-3.1%+12.1%$11.51B$1.98B127.875,765News CoveragePositive NewsUpcoming EarningsVTRSViatris2.2064 of 5 stars$9.26-1.6%$10.40+12.3%-26.3%$11.04B$14.74B-2.9232,000Upcoming EarningsShort Interest ↑ASNDAscendis Pharma A/S3.0771 of 5 stars$164.16-2.0%$223.07+35.9%+27.8%$10.24B$393.54M-26.141,017Analyst ForecastBBIOBridgeBio Pharma4.7141 of 5 stars$46.23-0.2%$61.50+33.0%+80.9%$8.79B$127.42M-13.10400Upcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies Summit Therapeutics Competitors Insmed Competitors Teva Pharmaceutical Industries Competitors Genmab A/S Competitors Moderna Competitors Dr. Reddy's Laboratories Competitors QIAGEN Competitors Viatris Competitors Ascendis Pharma A/S Competitors BridgeBio Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RYTM) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredMicrosoft's Next Big Bet?Microsoft just broke ground on a revolutionary power system that could deliver virtually limitless, carbon-fre...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RYTM Stock Alerts